- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00779012
A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)
May 10, 2017 updated by: Merck Sharp & Dohme LLC
Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis
The objective of this study is to prove reasonability of registration in Russian federation this new indication (ankylosing spondylitis [AS]) through evaluation of safety and efficacy rate of Remicade 5mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
Study Overview
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients 18 to 70 years of age.
- Males and female patients of reproductive potential (also includes women who have been postmenopaused <1 year) must use a reliable birth control method (abstinence, oral contraceptives, diaphragm prescribed by a physician, condom used with a spermicide, surgical sterilization) up until 6 months after the last Remicade infusion.
- Proven AS according to the modified New York criteria implying that included patients must have a pelvic x-ray showing the signs of sacroiliitis > grade 2 bilateral.
- Acute phase of disease during not less than last 3 months under condition of the everyday intake of some of NSAIDs in full daily dosage for at least 1 month before the initiation of the treatment, significant spinal pain (VAS > 4)during the last week prior to the inclusion into the study. In case of peripheral joints arthritis besides the measures mentioned above the absence of the efficacy of at least 2-times intraarticular injection of steroids (if only it is not contraindicated or not well tolerated) or sulfasalazine intake at a daily dose of 2-3 g for at least 4 months (if only it is not contraindicated or not well tolerated) should be established. In case of enthesitis inflammation besides the measures mentioned above the absence of the efficacy of at least 2-times local injection of steroids (if only it is not contraindicated or not well tolerated) should be established.
- Ability to comprehend the terms of the participation in the study, willing to follow all procedures and instructions and informed consent form signed before the beginning of the first procedures of the study (except several cases of chest x-ray).
- Screening for prevention of latent and active TB must be performed according to the local guidelines and/or the current SPC and alert card. This will include a PPD test and a Chest x-ray to be performed within 30 days prior to initiating treatment with Remicade.
Exclusion Criteria:
- Pregnant women, nursing mothers or a planned pregnancy within 6 months after the last infusion.
- Patients who have any concurrent systemic inflammatory condition with signs and symptoms that might confound the evaluations of benefit from Remicade, e.g. Lyme disease, or a rheumatic disease (lupus erythematosus, systemic scleroderma) with the joint affection and sacroileitis.
- Prior administration of Remicade or any other therapeutic agent targeted at reducing TNF (e.g.,Etanercept, pentoxifylline, thalidomide or anti-CD4+ antibody) within the previous 3 months.
- History of known allergies to murine proteins.
- Serious infections, such as hepatitis, pneumonia, pyelonephritis in the previous 3 months. Less serious infections in the previous 3 months, such as acute upper respiratory tract infection (colds) or uncomplicated urinary tract infection need not be considered exclusions at the discretion of the treating physician.
- Any chronic infections in the acute phase, e.g. upper respiratory tract infections or other localization (chronic bronchitis, pneumonia, pyelonephritis, cholecystitis, hepatitis etc.).
- Documented HIV infection.
- Positive hepatitis B and C test without clinical signs of the disease.
- Current skin psoriasis, nonspecific ulcerative colitis and Crohn's disease.
- History of opportunistic infections such as herpes zoster within 2 months of screening. Evidence of active CMV, active pneumocystis carinii, drug resistant atypical mycobacterium infections, etc.
- Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, neurological or cerebral disease.
- Any currently known malignancy or pre-malignant lesions or any history of malignancy within the past 5 years.
- Active and/or latent TB or previous history of TB.
- Non-stable doses of the basic steroid therapy or NSAID therapy within 4 weeks before the inclusion into the study.
- Supportive prednisone therapy >10 mg/day.
- Patients with moderate or severe heart failure (NYHA class III/IV).
- Septic arthritis (or infected joint implant) within at least last 12 months.
- Necessity in the use of other medicinal products.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Remicade
|
Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluation of the efficacy and safety rate of the study drug, Remicade, in decreasing symptoms and signs of AS (pain) as well as the evaluation of the safety and the tolerance of the profile of the drug.
Time Frame: The patient undergoes the complex evaluation of the articular status every 6 -8 weeks.
|
The patient undergoes the complex evaluation of the articular status every 6 -8 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of achievement of at least 50% ASAS improvement (compared to baseline) 8 weeks after the last infusion of Remicade.
Time Frame: 8 weeks after the last infusion of Remicade
|
8 weeks after the last infusion of Remicade
|
Frequency of at least 50% of the stable improvement of ASAS (compared to baseline) over a period of the supportive treatment phase (after infusion 3, up to 6 to 8 weeks after the last infusion of Remicade)
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Frequency of at least 20%, 50%, and 75% of ASAS improvement (compared to baseline) 6 to 8 weeks after the last infusion of Remicade
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Change in AS activity (BASDAI) compared to baseline 6 to 8 weeks after the last infusion of Remicade
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Change of global evaluation of the activity of the disease by patient (VAS) compared to baseline 6 to 8 weeks after the last infusion of Remicade
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Change of the functional status of the patients (BASFI) compared to baseline 6 to 8 weeks after the last infusion of Remicade
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Change of spine motion compared to baseline 6 to 8 weeks after the last infusion of Remicade
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Change of spinal pain compared to baseline 6 to 8 weeks after the last infusion of Remicade
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Change of sensation of fatigue compared to baseline 6 to 8 weeks after the last infusion of Remicade (VAS)
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Change of pain in peripheral joints compared to baseline 6 to 8 weeks after the last infusion of Remicade (VAS)
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Change of the duration of the morning stiffness in peripheral joints compared to baseline 6 to 8 weeks after the last infusion of Remicade (VAS)
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Change of the number of tender joints compared to baseline 6 to 8 weeks after the last infusion of Remicade
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Change of the number of inflamed joints compared to baseline 6 to 8 weeks after the last infusion of Remicade
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Change of the number of the transformed enthesitises compared to baseline 6 to 8 weeks after the last infusion of Remicade
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Change of the duration of the morning spinal stiffness compared to baseline 6 to 8 weeks after the last infusion of Remicade
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Change of serum C-reactive protein and ESR compared to baseline 6 to 8 weeks after the last infusion of Remicade
Time Frame: Up to 8 weeks after the last infusion of Remicade
|
Up to 8 weeks after the last infusion of Remicade
|
Quality of life evaluation in accordance with SF-36
Time Frame: 6-8 weeks after visit 10 (before the last infusion of Remicade) or in case of discontinuation
|
6-8 weeks after visit 10 (before the last infusion of Remicade) or in case of discontinuation
|
Obtaining of additional information on the safety profile of the tested product over a period of the study.
Time Frame: up to 54 weeks
|
up to 54 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2004
Primary Completion (Actual)
June 1, 2007
Study Completion (Actual)
June 1, 2007
Study Registration Dates
First Submitted
October 23, 2008
First Submitted That Met QC Criteria
October 23, 2008
First Posted (Estimate)
October 24, 2008
Study Record Updates
Last Update Posted (Actual)
May 11, 2017
Last Update Submitted That Met QC Criteria
May 10, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P04042
Plan for Individual participant data (IPD)
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spondylitis, Ankylosing
-
Shanghai Junshi Bioscience Co., Ltd.Sponsor GmbHRecruitingActive Ankylosing SpondylitisChina
-
AbbVieBoehringer IngelheimCompletedAnkylosing Spondylitis (AS)
-
Sun Yat-sen UniversityUnknownEarly Ankylosing Spondylitis
-
Tongji HospitalWuhan Central Hospital; Wuhan Hospital of Traditional Chinese MedicineRecruitingAnkylosing Spondylitis (AS)China
-
Chinese University of Hong KongCompletedAnkylosing Spondylitis(AS)China
-
AbbVieCompletedAnkylosing Spondylitis (AS)United States, Australia, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Spain, Sweden, United Kingdom
-
AbbVieCompletedAnkylosing Spondylitis (AS)Taiwan
-
Jiangsu vcare pharmaceutical technology co., LTDRecruitingActive Ankylosing SpondylitisChina
-
Tianjin Hemay Pharmaceutical Co., LtdCompletedActive Ankylosing SpondylitisChina
-
Assiut UniversityUnknownActive Sacroiliitis in Ankylosing Spondylitis
Clinical Trials on Infliximab
-
Onze Lieve Vrouwe GasthuisSanteonUnknown
-
Merck Sharp & Dohme LLCIntegrated Therapeutics GroupTerminatedRheumatoid Arthritis
-
Diakonhjemmet HospitalSouth-Eastern Norway Regional Health AuthorityCompletedRheumatoid Arthritis | Crohn's Disease | Ulcerative Colitis | Psoriatic Arthritis | Spondyloarthritis | Psoriasis ChronicNorway
-
PfizerCompleted
-
Centre hospitalier de l'Université de Montréal...Ottawa Hospital Research Institute; Maisonneuve-Rosemont Hospital; Niagara Health... and other collaboratorsRecruiting
-
NYU Langone HealthWithdrawnInflammatory Bowel Disease
-
PfizerCompletedPsoriasis Vulgaris | Pustular Psoriasis | Psoriasis Arthropathica | Erythrodermic PsoriasisJapan
-
European Organisation for Research and Treatment...CompletedMyelodysplastic SyndromesFrance, Belgium, Netherlands, Czech Republic, Italy, Germany
-
Janssen Research & Development, LLCJanssen Biologics BVCompletedUlcerative ColitisUnited States, France, United Kingdom, Belgium, Switzerland, Israel, Canada, Australia, Netherlands, New Zealand, Austria, Germany, Denmark, Czechia, Argentina
-
BiocadCompletedAnkylosing SpondylitisRussian Federation, Belarus